{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["27(8)"],"submitter":["Fakih M"],"funding":["Amgen Inc"],"pubmed_abstract":["<h4>Background</h4>The KRAS p.G12C mutation has recently become an actionable drug target. To further understand KRAS p.G12C disease, we describe clinicopathologic characteristics, treatment patterns, overall survival (OS), and real-world progression-free survival (rwPFS) in patients with metastatic colorectal cancer (mCRC), KRAS p.G12C mutations (KRAS G12C), and other KRAS mutations (KRAS non-G12C) using a de-identified database.<h4>Patients and methods</h4>Clinical and tumor characteristics, including treatments received, genomic profile, and clinical outcomes were assessed for patients from a US clinical genomic database with mCRC diagnosed between January 1, 2011, and March 31, 2020, with genomic sequencing data available.<h4>Results</h4>Of 6477 patients with mCRC (mCRC cohort), 238 (3"],"journal":["The oncologist"],"pagination":["663-674"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9355827"],"repository":["biostudies-literature"],"pubmed_title":["Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer."],"pmcid":["PMC9355827"],"pubmed_authors":["Kopetz S","Fakih M","Aggarwal S","Rehn M","Chan E","Chia V","Tu H","Hsu H"],"additional_accession":[]},"is_claimable":false,"name":"Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer.","description":"<h4>Background</h4>The KRAS p.G12C mutation has recently become an actionable drug target. To further understand KRAS p.G12C disease, we describe clinicopathologic characteristics, treatment patterns, overall survival (OS), and real-world progression-free survival (rwPFS) in patients with metastatic colorectal cancer (mCRC), KRAS p.G12C mutations (KRAS G12C), and other KRAS mutations (KRAS non-G12C) using a de-identified database.<h4>Patients and methods</h4>Clinical and tumor characteristics, including treatments received, genomic profile, and clinical outcomes were assessed for patients from a US clinical genomic database with mCRC diagnosed between January 1, 2011, and March 31, 2020, with genomic sequencing data available.<h4>Results</h4>Of 6477 patients with mCRC (mCRC cohort), 238 (3","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-22T11:29:35.412Z","creation":"2025-04-05T23:58:53.716Z"},"accession":"S-EPMC9355827","cross_references":{"pubmed":["35472176"],"doi":["10.1093/oncolo/oyac077"]}}